Cite
FRI496 - SPARC negatively correlates with prognosis after transarterial chemoembolization and facilitates growth and metastasis of hepatocellular carcinoma via ERK/MMP signaling pathways.
MLA
Liu, Yao, et al. “FRI496 - SPARC Negatively Correlates with Prognosis after Transarterial Chemoembolization and Facilitates Growth and Metastasis of Hepatocellular Carcinoma via ERK/MMP Signaling Pathways.” Journal of Hepatology, vol. 73, Aug. 2020, pp. S641–42. EBSCOhost, https://doi.org/10.1016/S0168-8278(20)31749-9.
APA
Liu, Y., Feng, Y., & Wang, X. (2020). FRI496 - SPARC negatively correlates with prognosis after transarterial chemoembolization and facilitates growth and metastasis of hepatocellular carcinoma via ERK/MMP signaling pathways. Journal of Hepatology, 73, S641–S642. https://doi.org/10.1016/S0168-8278(20)31749-9
Chicago
Liu, Yao, Ying Feng, and Xianbo Wang. 2020. “FRI496 - SPARC Negatively Correlates with Prognosis after Transarterial Chemoembolization and Facilitates Growth and Metastasis of Hepatocellular Carcinoma via ERK/MMP Signaling Pathways.” Journal of Hepatology 73 (August): S641–42. doi:10.1016/S0168-8278(20)31749-9.